DNM1L and Parkinson disease: There is increasing evidence of dysregulated Drp1 in the context of a variety of diseases, including neurodegeneration such as Parkinson’s (Han et al, 2020), cardiovascular diseases (Zunino et al, 2007; Sharp et al, 2014; Kim et al, 2015) and cancer (Rehman et al, 2012; Kashatus et al, 2015; Serasinghe et al, 2015).